Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + ramucirumab + paclitaxel
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Sintilimab + ramucirumab + paclitaxel is an investigational triple-combination regimen being evaluated for the treatment of advanced gastric cancer. The regimen consists of three distinct therapeutic agents: **sintilimab** (Tyvyt), a recombinant fully human IgG4 monoclonal antibody that targets the PD-1 immune checkpoint to restore anti-tumor T-cell activity; **ramucirumab** (Cyramza), a human IgG1 monoclonal antibody that acts as a VEGFR-2 antagonist to inhibit tumor angiogenesis; and **paclitaxel**, a taxane-class small molecule chemotherapy that stabilizes microtubules to arrest cell division. This combination is primarily being studied in Phase 2 clinical trials (e.g., NCT06564298) for patients who have experienced short-term recurrence after postoperative adjuvant therapy, with the goal of leveraging the synergistic effects of immune checkpoint blockade, anti-angiogenic therapy, and cytotoxic chemotherapy.
- Other names
- sintilimab combined with ramucirumab and paclitaxel
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on sintilimab + ramucirumab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + ramucirumab + paclitaxel.